Stay updated on Nivolumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab in Hodgkin Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page’s footer shows an updated site/system software revision from v3.5.2 to v3.5.3, without altering the underlying study details.SummaryDifference0.0%

- Check19 days agoChange DetectedAdded Revision: v3.5.2; removed Revision: v3.5.0.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no impact on study content or functionality.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded Revision: v3.4.2. Deleted: the government funding lapse notice and the earlier Revision: v3.4.1; these are administrative changes and do not affect the study content, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check92 days agoChange DetectedA funding/operational status notice was added, and the site revision tag updated to v3.4.1, replacing the previous v3.4.0 tag.SummaryDifference0.3%

Stay in the know with updates to Nivolumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.